Potential to inhibit growth of atherosclerotic plaque development through modulation of macrophage neopterin/7,8-dihydroneopterin synthesis

British Journal of Pharmacology

Volumn 153, Issue 4, 2008, Pages 627-635

  Gieseg, S P ^a   Crone, E M ^a   Flavall, E A ^a   Amit, Z ^a  

^a UNIVERSITY OF CANTERBURY   (New Zealand)

Author keywords

7,8 dihydroneopterin; Antioxidant; Atherosclerosis; Indoleamine 2,3 dioxygenase; Inflammation; Interferon; Low density lipoprotein; Macrophage apoptosis; Neopterin; Pro oxidant

Indexed keywords

7,8 DIHYDRONEOPTERIN; GAMMA INTERFERON; HYPOCHLORITE; LOW DENSITY LIPOPROTEIN; NEOPTERIN; NITRIC OXIDE; PEROXY RADICAL; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROTIC PLAQUE; CELL PROTECTION; CYTOKINE RELEASE; CYTOTOXICITY; FENTON REACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID OXIDATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CALCIUM; FREE RADICAL SCAVENGERS; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; MACROPHAGES; NEOPTERIN; OXIDANTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 39449093488     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707408     Document Type: Review

References (108)

1. Anwaar I, Gottsater A, Hedblad B, Palmqvist B, Mattiasson I, Lindgarde F (1998). Endothelial derived vasoactive factors and leukocyte derived inflammatory mediators in subjects with asymptomatic atherosclerosis. Angiology 49: 957-966.
2. Aviram M, Rosenblat M, Etzioni A, Levy R (1996). Activation of NADPH oxidase is required for macrophage mediated oxidation of low density lipoprotein. Metabolism 45: 1069-1079.
3. Awandare GA, Goka B, Boeuf P, Tetteh JKA, Kurtzhals JAL, Behr C et al. (2006). Increased levels of inflammatory mediators in children with severe Plasmodium falciparum malaria with respiratory distress. J Infect Dis 194: 1438-1446.
4. Baier-Bitterlich G, Baier G, Fuchs D, Block G, Hausen A, Utermann G et al. (1996). Role of 7,8-dihydroneopterin in T-cell apoptosis and HTLV-1 transcrition in vitro. Oncogene 13: 2281-2285.
5. Baier-Bitterlich G, Fuchs D, Murr C, Reibnegger G, Werner-Felmayer G, Sgonc R et al. (1995). Effect of neopterin and 7,8-dihydroneopterin on tumor necrosis factor-alpha induced programmed cell death. FEBS Lett 364: 234-238.
6. Baird SK, Reid L, Hampton M, Gieseg SP (2005). OxLDL induced cell death is inhibited by the macrophage synthesised pterin, 7,8-dihydroneopterin, in U937 cells but not THP-1 cells. Biochem Biophys Acta 1745: 361-369.
7. Balogh A, Mittermayr M, Schlager A, Balogh D, Schobersberger W, Fuchs D et al. (2005). Mechanism of neopterin-induced myocardial dysfunction in the isolated perfused rat heart. Biochimica Et Biophysica Acta-General Subjects 1724: 17-22.
8. Bowry VW, Ingold KU, Stocker S (1992). Vitamin E in human low-density lipoprotein, when and how this antioxidant becomes a pro-oxidant. Biochem J 288: 341-344.
9. Bowry VW, Stocker R (1993). Tocopherol-mediated peroxidation. The prooxidant effect of vitamin E on radical-initiated oxidation of human low-density lipoprotein. J Am Chem Soc 115: 6029-6044.
10. Brown AJ, Leong S, Dean RT, Jessup W (1997). 7-Hydroperoxycholesterol and its products in oxidised low density lipoprotein and human atherosclerotic plaque. J Lipid Res 38: 1730-1745.
11. Buettner GR (1988). In the absence of catalytic metals ascorbate does not autoxidize at pH 7: Ascorbate as a test for catalytic metals. J Biochem Biophys Methods 16: 27-40.
12. Carpenter KLH, Taylor SE, Van der Veen C, Williamson BK, Ballantine JA, Mitchinson MJ (1995). Lipids and oxidised lipids in human atherosclerosis lesions at different stages of development. Biochim Biophys Acta 1256: 141-150.
13. Chisolm GM, Hazen SL, Fox PL, Cathcart MK (1999). The oxidation of lipoproteins by monocytes-macrophage: Biochemical and biological mechanisms. J Biol Chem 274: 25959-25962.
14. Christen S, Peterhans E, Stocker R (1990). Antioxidant activities of some tryptophan metabolities: possible implication for inflammatory diseases. Proc Natl Acad Sci USA 87: 2506-2510.
15. Christen S, Thomas SR, Garner B, Stocker R (1994). Inhibition by interferon-gamma of human mononuclear cell-mediated low density lipoprotein oxidation: participation of tryptophan metabolism along the kynurenine pathway. J Clin Invest 93: 2149-2158.
16. Clare K, Hardwick SJ, Carpenter KL, Weeratunge N, Mitchinson MJ (1995). Toxicity of oxysterols to human monocyte-macrophages. Atherosclerosis 118: 67-75.
17. Clement MV, Ramalingam J, Long LH, Halliwell B (2001). The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. Antioxid Redox Signal 3: 157-163.
18. Daugherty A, Dunn JL, Rateri DL, Heinecke JW (1994). Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerosis lesions. J Clin Med 94: 437-444.
19. Enzinger C, Wirleitner B, Lutz C, Bock G, Tomaselli B, Baier G et al. (2002a). 7,8-Dihydroneopterin induces apoptosis of Jurkat T-lymphocytes via a Bcl-2-sensitive pathway. Eur J Cell Biol 81: 197-202.
20. Enzinger C, Wirleitner B, Spottl N, Bock G, Fuchs D, Baier-Bitterlich G (2002b). Reduced pteridine derivatives induce apoptosis in PC12 cells. Neurochem Int 41: 71-78.
21. Fabjan JS, Abuja PM, Schaur RJ, Sevanian A (2001). Hypochlorite induces the formation of LDL(-), a potentially atherogenic low density lipoprotein subspecies. FEBS Lett 499: 69-72.
22. Fijen JW, Kobold AC, de Boer P, Jones CR, van derWerf TS, Tervaert JW et al. (2000). Leukocyte activation and cytokine production during experimental human endotoxemia. Eur J Intern Med 11: 89-95.
23. Firth CA, Yang Y, Gieseg SP (2007). Lipid oxidation predominates over protein hydroperoxide formation in human monocyte-derived macrophages exposed to aqueous peroxyl radicals. Free Rad Res 41: 839-848.
24. Fuchs D, Hausen A, Kofler M, Kosanowski H, Reibnegger G, Wachter H (1984). Neopterin as an index of immune response in patients with tuberculosis. Lung 162: 337-346.
25. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H (1988). Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 9: 150-155.
26. Garcia-Moll X, Coccolo F, Cole D, Kaski JC (2000a). Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol 35: 956-962.
27. Garcia-Moll X, Cole D, Zouridakis E, Kaski JC (2000b). Increased serum neopterin: a marker of coronary artery disease activity in women. Heart 83: 346-350.
28. Gieseg SP, Cato S (2003). Inhibition of THP-1 cell-mediated low-density lipoprotein oxidation by the macrophage-synthesised pterin, 7,8- dihydroneopterin. Redox Rep 8: 113-119.
29. Gieseg SP, Duggan S, Rait C, Platt A (2002). Protein and thiol oxidation in cells exposed to peroxyl radicals, is inhibited by the macrophage synthesised pterin 7,8-dihydroneopterin. Biochim Biophys Acta 1591: 139-145.
30. Gieseg SP, Glubb D, Maghzal G (2001a). Protection of erythrocytes by the macrophage synthesized antioxidant 7,8 dihydroneopterin. Free Rad Res 34: 123-136.
31. Gieseg SP, Maghzal G, Glubb D (2000). Inhibition of haemolysis by the macrophage synthesized antioxidant, 7,8-dihydroneopterin. Redox Rep 5: 97-100.
32. Gieseg SP, Pearson J, Firth CA (2003). Protein hydroperoxides are a major product of low density lipoprotein oxidation during copper, peroxyl radical and macrophage-mediated oxidation. Free Rad Res 37: 983-991.
33. Gieseg SP, Reibnegger G, Wachter H, Esterbauer H (1995). 7,8-Dihydroneopterin inhibits low density lipoprotein oxidation in vitro. Evidence that this macrophage secreted pteridine is an antioxidant. Free Rad Res 23: 123-136.
34. Gieseg SP, Whybrow J, Glubb D, Rait C (2001b). Protection of U937 cells from free radical damage by the macrophage synthesized antioxidant 7,8 dihydroneopterin. Free Rad Res 35: 311-318.
35. Goldstein JL, Ho YK, Basu SK, Brown MS (1979). Binding-site on macrophages that mediates uptake and degradation of acetylated low-density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 76: 333-337.
36. Greilberger J, Oettl K, Cvirn G, Reibnegger G, Jurgens G (2004). Modulation of LDL oxidation by 7,8-dihydroneopterin. Free Rad Res 38: 9-17.
37. Gruber A, Murr C, Wirleitner B, Werner-Felmayer G, Fuchs D (2000). Histamine suppresses neopterin production in the human myelomonocytoma cell line THP-1. Immunol Lett 72: 133-136.
38. Hazen SL, Gaut JP, Crowley JR, Hsu FF, Heinecke JW (2000). Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. Biochem J 352: 693-699.
39. Hegyi L, Skepper JN, Cary NRB, Mitchinson MJ (1996). Foam cell apoptosis and the development of the lipid core of human atherosclerosis. J Pathol 180: 423-429.
40. Herpfer I, Greilberger J, Ledinski G, Widner B, Fuchs D, Jurgens G (2002). Neopterin and 7,8-dihydroneopterin interfere with low density lipoprotein oxidation mediated by peroxynitrite and/or copper. Free Rad Res 36: 509-520.
41. Higuras V, Raya A, Rodrigo JM, Serra MA, Roma J, Romero FJ (1994). Interferon decreases serum lipid peroxidation products of hepatitis c patients. Free Rad Biol Med 16: 131-133.
42. Hoff F, O'Neil J, Chisolm III GM, Cole TB, Quehenberger O, Esterbauer H et al. (1989). Modification of low density lipoproteins with 4-hydroxylnonenal induces uptake by macrophges. Aterosclerosis 9: 538-549.
43. Hoffmann G, Gollnick F, Meyer R (2002). Neopterin inhibits ATP-induced calcium release in alveolar epithelial cells in vitro. Mediators Inflamm 11: 181-185.
44. Hoffmann G, Kenn S, Wirleitner B, Deetjen C, Frede S, Smolny M et al. (1998). Neopterin induces nitric oxide-dependent apoptosis in rat vascular smooth muscle cells. Immunobiology 199: 63-73.
45. Hoffmann G, Schobersterger W, Frede S, Pe zer L, Fandrey J, Wachter H et al. (1996). Neopterin activates transcription factor nuclear factor-kB in vascular smooth muscle cells. FEBS 391: 181-184.
46. Jessup W, Simpson JA, Dean RT (1993). Does superoxide radical have a role in macrophage-mediated oxidative modification of LDL. Atherosclerosis 99: 107-120.
47. Johnston DT, Gagos M, Raio N, Ragolia L, Shenouda D, Davis-Lorton MA et al. (2006). Alterations in serum neopterin correlate with thrombolysis in myocardial infarction risk scores in acute coronary syndromes. Coron Artery Dis 17: 511-516.
48. Kojima S, Icho T, Kajiwara Y, Kubota K (1992). Neopterin as an endogenous antioxidant. FEBS Lett 304: 163-166.
49. Lassila R (1993). Inflamation in atheroma: implications for plaque rupture and platelet-collagen interaction. Eur Heart J 14: 94-97.
50. Leeuwenburgh C, Rasmussen JE, Hsu F, Mueller DM, Pennathur S, Heinecke JW(1997). Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 272: 3520-3526.
51. Libby P, Ridker PM, Maseri A (2002). Inflammation and atherosclerosis. Circulation 105: 1135-1143.
52. Marchant CE, Law NS, Vanderveen C, Hardwick SJ, Carpenter KLH, Mitchinson MJ (1995). Oxidized low-density-lipoprotein is cytotoxic to human monocyte-macrophages: protection with lipophilic antioxidants. FEBS Lett 358: 175-178.
53. Margreiter J, Schlager A, Balogh A, Maier H, Balogh D, Lindner KH et al. (2000). Exogenous neopterin causes cardiac contractile dysfunction in the isolated perfused rat heart. J Mol Cell Cardiol 32: 1265-1274.
54. Margreiter R, Fuchs D, Hausen A, Huber C, Reibnegger G, Spielberger M et al. (1983). Neopterin as a new biomarker for the diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplant 36: 650-653.
55. Martinet W, Kockx MM (2001). Apoptosis in atherosclerosis: Focus on oxidized lipids and inflammation. Curr Opin Lipidol 12: 535-541.
56. Moutabarrik A, Takahara S, Nakanishi I, Kokado Y, Takano Y, Kameoka H et al. (1994). Interferon-gamma stimulates neopterin release from cultured kidney epithelial-cells. Scand J Immunol 39: 27-30.
57. Muller MM, Curtis H, Herold M, Huber CH (1991). Neopterin in clinical practice. Clin Chim Acta 201: 1-16.
58. Neurauter G, Wirleitner B, Laich A, Schennach H, Weiss G, Fuchs D (2003). Atorvastatin suppresses interferon-gamma-induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin Exp Immunol 131: 264-267.
59. Niu XW, Zammit V, Upston JM, Dean RT, Stocker R (1999). Coexistence of oxidized lipids and alpha-tocopherol in all lipoprotein density fractions isolated from advanced human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 19: 1708-1718.
60. Oettl K, Dikalov S, Freisleben HJ, Mlekusch W, Reibnegger G (1997). Spin trapping study of antioxidant properties of neopterin and 7,8-dihydroneopterin. Biochem Biophy Res Commmun 234: 774-778.
61. Oettl K, Greilberger J, Dikalov S, Reibnegger G (2004). Interference of 7,8-dihydroneopterin with peroxynitrite-mediated reactions. Biochem Biophys Res Commun 321: 379-385.
62. Oettl K, Wirleitner B, Baier BG, Grammer T, Fuchs D, Reibnegger G (1999). Formation of oxygen radicals in solutions of 7,8-dihydroneopterin. Biochem Biophys Res Commun 264: 262-267.
63. Platt AA, Gieseg SP (2003). Protein thiol inhibited protein hydroperoxide formation. Redox Rep 8: 81-86.
64. Razumovitch JA, Fuchs D, Semenkova GN, Cherenkevich SN (2004). Influence of neopterin on generation of reactive species by myeloperoxidase in human neutrophils. Biochim Biophys Acta 1672: 46-50.
65. Reibnegger G, Boonpucknavig V, Fuchs D, Hausen A, Schmutzhard E, Wachter H (1984). Urinary neopterin is elevated in patients with malaria. Trans R Soci Trop Med Hyg 78: 545-546.
66. Reibnegger G, Egg D, Fuchs D, Gunther R, Hausen A, Werner ER et al. (1986). Urinary neopterin reflects clinical activity in patients with rheumtoid arthritis. Arthritis Rheum 29: 1063-1070.
67. Reibnegger G, Krainer M, Herold M, Ludwig H, Wachter H, Huber H (1991). Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 51: 6250-6253.
68. Rieder J, Marth C, Hoffmann G (2006). Effect of neopterin derivatives on mitochondrial dehydrogenase activity in ovarian carcinoma cell lines in vitro. Pteridines 17: 115-120.
69. Rippin JJ (1992). Analysis of fully oxidised neopterin in serum by high-performance liquid chromatography. Clin Chem 38: 1722-1724.
70. Rudzite V, Jurika E, Schroecksnadel K, Kalnins U, Erglis A, Trusinskis K et al. (2005). Usefulness of neopterin, C-reactive protein, homocysteine, pyridoxal-5-phosphate, and phospholipid determination in coronary artery disease. Pteridines 16: 15-21.
71. Schewe T, Kuhn H (1991). Do 15-lipoxygenases have a common biological role? TIBS 16: 369-373.
72. Schobersterger W, Hoffmann G, Hobisch-Hagen P, Bock G, Volkl H, Baier-Bitterlich G et al. (1996). Neopterin and 7,8-dihydroneopterin induce apoptosis in the rat alveolar epithelial cell line L2. FEBS Lett 397: 263-268.
73. Schoedon G, Troppmair J, Fontana A, Huber C, Curtius HC, Niederwieser A (1987). Biosynthesis and metabolism of pterins in peripheral-blood mononuclear-cells and leukemia lines of man and mouse. Eur J Biochem 166: 303-310.
74. Schraufstatter IU, Browne K, Harris A, Hyslop PA, Jackson JH, Quehenberger O et al. (1990). Mechanisms of hypochlorite injury of target cells. J Clin Invest 85: 554-562.
75. Schroder JM, Mrowietz U, Morita E, Christophers E (1987). Purification and partial biochemical characterisation of a human monocyte derived neutrophil activation peptide that lacks interleukin activity. J Immunol 139: 3474-3483.
76. Schroecksnadel K, Frick B, Kaser S, Wirleitner B, Ledochowski M, Mur E et al. (2003). Moderate hyperhomocysteinaemia and immune activation in patients with rheumatoid arthritis. Clin Chim Acta 338: 157-164.
77. Schumacher M, Eder B, Tatzber F, Kaufmann P, Esterbauer H, Klein W (1992). Neopterin levels in patients with coronary artery disease. Atherosclerosis 94: 87-88.
78. Schumacher M, Halwachs G, Tatzber F, Fruhwald FM, Zweiker R, Watzinger N et al. (1997). Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol 30: 703-707.
79. 3. J Leukoc Biol 59: 555-561.
80. Shen R (1994). Inhibition of luminol enhanced chemiluminescence by reduced pterins. Arch Biochem Biophys 310: 60-63.
81. Shukla N, Maher J, Masters JD, Angelini G, Jeremy JY (2006). Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis 187: 238-250.
82. Spottl N, Wirleitner B, Boeck G, Widner B, Fuchs D, Baier-Bitterlich G (2000). Reduced pteridine derivatives induce apoptosis in human neuronal NT2/HNT cells. Immunobiology 201: 478-491.
83. Stadler N, Lindner RA, Davies MJ (2004). Direct detection and quantification of transition metal ions in human atherosclerotic plaques: Evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 24: 949-954.
84. Steinberg D (1995). The oxidative modification hypothesis of atherogenesis: strengths and weakness. In: Woodford FP, Davignon J, Sniderman A (eds). Atherosclerosis X: proceedings of the 10th International Symposium on Atherosclerosis, Montreal, October 9-14, 199. Elsevier: Netherlands, pp 25-29.
85. Steinbrecher UP, Lougheed M, Kwan WC, Dirks M (1989). Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J Biol Chem 264: 15216-15223.
86. Strohmaier W, Poigenfurst J, Mauritz W (1996). Neopterin blood levels: A basis for deciding to use antibiotics in intensive care unit (ICU) patients. Pteridines 7: 1-4.
87. Tatzber F, Rabl H, Koriska K, Erhart U, Puhl H, Weag G et al. (1991). Elivated serum neopterin levels in atherosclerosis. Atherosclerosis 89: 203-208.
88. Thomas SR, Mohr D, Stocker R (1994). Nitric-oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. J Biol Chem 269: 14457-14464.
89. Thomas SR, Witting PK, Stocker R (1996). 3-Hydroxyanthranilic acid is an efficient, cell-derived co-antioxidant for alpha-tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation. J Biol Chem 271: 32714-32721.
90. Van Der Wal AC, Becker AE (1999). Atherosclerotic plaque rupture: Pathologic basis of plaque stability and instability. Cardiovasc Res 41: 334-344.
91. Wachter H, Fuchs D, Hausen A, Reibnegger G, Weiss G, Werner ER et al. (1992). Neopterin: Biochemistry Methods Clinical Applications. Walter de Gruyter: Berlin and New York.
92. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER (1989). Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 27: 81-141.
93. Walter RB, Fuchs D, Weiss G, Walter TR, Reinhart WH (2003). HMG-Coa reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease. Clin Chem Lab Med 41: 1314-1319.
94. Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H (1987). Simultaneous determination of neopterin and creatine in serum with solid phase extraction and on line elution liquid chromatography. Clin Chem 33: 2028-2033.
95. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H (1990). Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer Res 50: 2863-2867.
96. Westermann J, Thiemann F, Gerstner L, Tatzber F, Kozak I, Bertsch T et al. (2000). Evaluation of a new simple and rapid enzyme-linked immunosorbent assay kit for neopterin determination. Clin Chem Lab Med 38: 345-353.
97. Whiteman M, Rose P, Siau JL, Cheung NS, Tan GS, Halliwell B et al. (2005). Hypochlorous acid-mediated mitochondrial dysfunction and apoptosis in human hepatoma HEPG2 and human fetal liver cells: role of mitochondrial permeability transition. Free Rad Biol Med 38: 1571-1584.
98. Widner B, Baier-Bitterlich G, Wede I, Wirleitner B, Fuchs D (1998). Neopterin derivates modulate the nitration of tyrosine by peroxynitrite. Biochem Biophys Res Commun 248: 341-346.
99. Widner B, Mayr C, Wirleitner B, Fuchs D (2000). Oxidation of 7,8-Dihydroneopterin by hypochlorous acid yields neopterin. Biochem Biophys Res Commun 275: 307-311.
100. Wirleitner B, Baier-Bitterlich G, Boeck G, Widner B, Fuchs D (1998). 7,8-dihydroneopterin-induced apoptosis in Jurkat T lymphocytes: A comparison with anti-Fas-and hydrogen peroxide-mediated cell death. Biochem Pharmacol 56: 1181-1187.
101. Wirleitner B, Czaputa R, Oettl K, Bock G, Widner B, Reibnegger G et al. (2001). Induction of apoptosis by 7,8-dihydroneopterin: involvement of radical formation. Immunobiology 203: 629-641.
102. Wirleitner B, Reider D, Ebner S, Bock G, Widner B, Jaeger M et al. (2002). Monocyte-derived dendritic cells release neopterin. J Leukoc Biol 72: 1148-1153.
103. Woll E, Weiss G, Fuchs D, Lang F, Wachter H (1993). Effect of pteridine derivates on intracellular calcium concentration in human monocytic cells. FEBS 318: 246-252.
104. Woods AA, Linton SM, Davies MJ (2003). Detection of HOCl-mediated protein oxidation products in the extracellular matrix of human atherosclerotic plaques. Biochem J 370: 729-735.
105. Yan LJ, Lodge JK, Traber MG, Matsugo S, Packer L (1997). Comparison between copper-mediated and hypochlorite-mediated modifications of human low density lipoproteins evaluated by protein carbonyl formation. J Lipid Res 38: 992-1001.
106. Ylaherttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S et al. (1989). Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84: 1086-1095.
107. Yokoyama K, Tajima M, Yoshida H, Nakayama M, Tokutome G, Sakagami H et al. (2002). Plasma pteridine concentrations in patients with chronic renal failure. Nephrol Dialysis Transplant 17: 1032-1036.
108. Yuksekol I, Ozkan M, Akgul O, Tozkoparan E, Al-Rashed M, Balkan A et al. (2003). Urinary neopterin measurement as a non-invasive diagnostic method in pulmonary tuberculosis. Int J Tuberculosis Lung Dis 7: 771-776.